Malco Rossi

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8800622/publications.pdf

Version: 2024-02-01

331259 344852 1,554 66 21 36 h-index citations g-index papers 69 69 69 2236 all docs docs citations times ranked citing authors

#	Article	IF	CITATIONS
1	Genetic Diagnosis in Movement Disorders. Use of Whole-Exome Sequencing in Clinical Practice. Tremor and Other Hyperkinetic Movements, 2022, 12, 12.	1.1	3
2	Nomenclature of Genetic Movement Disorders: Recommendations of the International Parkinson and Movement Disorder Society Task Force – An Update. Movement Disorders, 2022, 37, 905-935.	2.2	49
3	Heart rate variability and falls in Huntington's disease. Clinical Autonomic Research, 2021, 31, 281-292.	1.4	14
4	Assessment of Ataxia Rating Scales and Cerebellar Functional Tests: Critique and Recommendations. Movement Disorders, 2021, 36, 283-297.	2.2	52
5	<scp>Myoclonusâ€Ataxia</scp> Syndromes: A Diagnostic Approach. Movement Disorders Clinical Practice, 2021, 8, 9-24.	0.8	11
6	Drooling and dysphagia in Parkinson's disease. International Review of Movement Disorders, 2021, , 147-178.	0.1	0
7	Cardiac Involvement in Movement Disorders. Movement Disorders Clinical Practice, 2021, 8, 651-668.	0.8	3
8	Involuntary moaning in a Hispanic family with eight affected members. Parkinsonism and Related Disorders, 2021, 89, 206-208.	1.1	0
9	Correlation between 99mTc-TRODAT-1 SPECT and 18F-FDOPA PET in patients with Parkinson's disease: a pilot study. Radiologia Brasileira, 2021, 54, 232-237.	0.3	2
10	Lowâ∈Frequency Oscillations at The Limbic Globus Pallidus Internus Seem to Be Associated With Premonitory Urges in Tourette's Syndrome. Movement Disorders, 2021, 36, 2966-2967.	2.2	3
11	How much time is needed in clinical practice to reach a diagnosis of clinically established Parkinson's disease?. Parkinsonism and Related Disorders, 2021, 92, 53-58.	1.1	6
12	Nosology and Phenomenology of Psychosis in Movement Disorders. Movement Disorders Clinical Practice, 2020, 7, 140-153.	0.8	6
13	Intermediate phenotype of ATP13A2 mutation in two Chilean siblings: Towards a continuum between parkinsonism and hereditary spastic paraplegia. Parkinsonism and Related Disorders, 2020, 81, 45-47.	1.1	4
14	Comment on: The Geographic Diversity of Spinocerebellar Ataxias (SCAs) in the Americas. Movement Disorders Clinical Practice, 2020, 7, 346-346.	0.8	1
15	Parkin Pleiotropy: Extremely Atypical Phenotypes in Patients With Compound Heterozygous Mutations. Tremor and Other Hyperkinetic Movements, 2020, 10, 26.	1.1	3
16	Design and validation of a new instrument to assess fear of falling in Parkinson's disease. Movement Disorders, 2019, 34, 1496-1504.	2.2	10
17	Re-emergent tremor provocation. Parkinsonism and Related Disorders, 2019, 66, 241-244.	1.1	7
18	Tourette syndrome: Clinical benefit with unilateral stimulation after bilateral pallidal implant. Movement Disorders, 2019, 34, 580-582.	2.2	2

#	Article	IF	CITATIONS
19	Sensitivity and specificity of different hand positions to assess upper limb rest tremor. Movement Disorders, 2019, 34, 575-579.	2.2	10
20	Apomorphine, More Evidence for An Old Drug: A Key for Therapy Generalization?. Movement Disorders Clinical Practice, 2019, 6, 118-119.	0.8	1
21	Latency of re-emergent tremor in Parkinson's disease is influenced by levodopa. Parkinsonism and Related Disorders, 2019, 61, 166-169.	1.1	9
22	Challenges in PD Patient Management After DBS: A Pragmatic Review. Movement Disorders Clinical Practice, 2018, 5, 246-254.	0.8	48
23	Open-Access Electronic Diary for Motor Fluctuation and Dyskinesia Evaluation in Parkinson Disease: Comparison With Paper Diary. Clinical Neuropharmacology, 2018, 41, 20-22.	0.2	4
24	Genetic Dystoniaâ€ataxia Syndromes: Clinical Spectrum, Diagnostic Approach, and Treatment Options. Movement Disorders Clinical Practice, 2018, 5, 373-382.	0.8	21
25	Postural Disorders and Antiparkinsonian Treatments in Parkinson Disease: An Exploratory Case-Control Study. Clinical Neuropharmacology, 2018, 41, 123-128.	0.2	8
26	Teaching Video Neurolmages: A treatable rare cause of chorea. Neurology, 2018, 91, e1089-e1089.	1.5	3
27	The genetic nomenclature of recessive cerebellar ataxias. Movement Disorders, 2018, 33, 1056-1076.	2.2	61
28	Rapid-onset dystonia-parkinsonism preceded by a single episode of subacute persisting hemiparesis: Expanding the ATP1A3-related disorders phenotype. Journal of the Neurological Sciences, 2018, 392, 44-45.	0.3	3
29	Dystonia in a Patient with Autosomal-Dominant Progressive External Ophthalmoplegia Type 1 Caused by Mutation in the POLG Gene. Movement Disorders Clinical Practice, 2017, 4, 266-269.	0.8	8
30	Expanding the phenotype of phosphomannomutase-2 gene congenital disorder of glycosylation: Cervical dystonia. Journal of the Neurological Sciences, 2017, 378, 52-54.	0.3	10
31	A multifactorial study on nutritional status, binge eating and physical activity as main factors directly influencing body weight in Parkinson's disease. Npj Parkinson's Disease, 2017, 3, 17.	2.5	8
32	Diagnostic Value of Combined Acute Levodopa Challenge and Olfactory Testing to Predict Parkinson's Disease. Movement Disorders Clinical Practice, 2017, 4, 824-828.	0.8	10
33	Is tremor related to celiac disease?. World Journal of Gastroenterology, 2017, 23, 4132.	1.4	1
34	Motor features in Parkinson's disease with normal olfactory function. Movement Disorders, 2016, 31, 1414-1417.	2.2	17
35	Phenytoin-Induced Chorea. Clinical Neuropharmacology, 2016, 39, 120.	0.2	5
36	How Do I Examine Postural Disorders in Parkinson's Disease?. Movement Disorders Clinical Practice, 2016, 3, 626-626.	0.8	4

#	Article	IF	CITATIONS
37	Ropiniroleâ€Induced Anterocollis in Parkinson's Disease. Movement Disorders Clinical Practice, 2016, 3, 91-92.	0.8	3
38	Facial tremors in patients with and without parkinsonism. Neurological Sciences, 2016, 37, 1999-2002.	0.9	6
39	Influence of white matter MRI hyper-intensities on acute l-dopa response in patients with Parkinson's disease. Parkinsonism and Related Disorders, 2016, 24, 126-128.	1.1	20
40	Comparison of Olfactory Identification Patterns among Parkinson's Disease Patients from Different Countries. Chemical Senses, 2016, 41, 77-83.	1.1	11
41	Olfactory Dysfunction Evaluation Is Not Affected by Comorbid Depression in Parkinson's Disease. Movement Disorders, 2015, 30, 1275-1279.	2.2	22
42	Management of constipation in Parkinson's disease. Expert Opinion on Pharmacotherapy, 2015, 16, 547-557.	0.9	45
43	Piano playing festination as initial symptom of Parkinson's disease. Parkinsonism and Related Disorders, 2015, 21, 417-418.	1.1	2
44	Autosomal dominant cerebellar ataxias: a systematic review of clinical features. European Journal of Neurology, 2014, 21, 607-615.	1.7	110
45	Teaching Neuro <i>Images</i> : Pisa syndrome in Parkinson disease. Neurology, 2014, 83, e177.	1.5	1
46	Movement Disorders in Autosomal Dominant Cerebellar Ataxias: A Systematic Review. Movement Disorders Clinical Practice, 2014, 1, 154-160.	0.8	103
47	Neurodegenerative Disorders: Dementia and Parkinsonism, Lumping Together or Splitting Apart?. , 2014, , $1\mathchar`1$ -16.		0
48	Amantadine improves gait in PD patients with STN stimulation. Parkinsonism and Related Disorders, 2013, 19, 316-319.	1.1	24
49	A Multi-Step Pathway Connecting Short Sleep Duration to Daytime Somnolence, Reduced Attention, and Poor Academic Performance: An Exploratory Cross-Sectional Study in Teenagers. Journal of Clinical Sleep Medicine, 2013, 09, 469-473.	1.4	70
50	Validation of a new scale to assess olfactory dysfunction in patients with Parkinson's disease. Parkinsonism and Related Disorders, 2012, 18, 358-361.	1.1	49
51	A double-blind, placebo-controlled, randomized, crossover pilot study of the safety and efficacy of multiple doses of intra-oral tropicamide films for the short-term relief of sialorrhea symptoms in Parkinson's disease patients. Journal of the Neurological Sciences, 2011, 310, 248-250.	0.3	35
52	Correlation between the Movement Disorders Society Unified Parkinson's Disease rating scale (MDS-UPDRS) and the Unified Parkinson's Disease rating scale (UPDRS) during l-dopa acute challenge. Parkinsonism and Related Disorders, 2011, 17, 705-707.	1.1	37
53	Nonmotor Symptoms Groups in Parkinson's Disease Patients: Results of a Pilot, Exploratory Study. Parkinson's Disease, 2011, 2011, 1-5.	0.6	9
54	Wearingâ€off scales in Parkinson's disease: Critique and recommendations. Movement Disorders, 2011, 26, 2169-2175.	2.2	101

#	Article	IF	CITATIONS
55	Decisionâ€making in Parkinson's disease patients with and without pathological gambling. European Journal of Neurology, 2010, 17, 97-102.	1.7	97
56	Actigraphic Evaluation of Motor Fluctuations in Patients with Parkinson's Disease. International Journal of Neuroscience, 2010, 120, 137-143.	0.8	14
57	Activityâ€"Rest Rhythm Abnormalities in Parkinson's Disease Patients are Related to Dopaminergic Therapy. International Journal of Neuroscience, 2010, 120, 11-16.	0.8	16
58	Parkinson's disease sleep scale, sleep logs, and actigraphy in the evaluation of sleep in parkinsonian patients. Journal of Neurology, 2009, 256, 1480-1484.	1.8	36
59	Sialorrhoea and Drooling in Patients with Parkinson's Disease. Drugs and Aging, 2008, 25, 1007-1019.	1.3	36
60	Validation of the sleep related items of the Non-motor Symptoms Questionnaire for Parkinson's disease (NMSQuest). Parkinsonism and Related Disorders, 2008, 14, 641-645.	1.1	14
61	Validation of a new scale for the evaluation of sialorrhea in patients with Parkinson's disease. Movement Disorders, 2007, 22, 107-111.	2.2	71
62	Accuracy of acute levodopa challenge for clinical prediction of sustained long-term levodopa response as a major criterion for idiopathic Parkinson's disease diagnosis. Movement Disorders, 2002, 17, 795-798.	2.2	73
63	Delayed intracerebral electrode infection after bilateral STN implantation for Parkinson's disease. Movement Disorders, 2001, 16, 168-170.	2.2	31
64	Unilateral radiofrequency lesion versus electrostimulation of posteroventral pallidum: A prospective randomized comparison. Movement Disorders, 1999, 14, 50-56.	2,2	108
65	Nicotinamide Adenine Dinucleotide Supplementation in Parkinson's Disease: A Potential Diseaseâ€Modifying Agent Targeting Multiple Pathways. Movement Disorders Clinical Practice, 0, , .	0.8	0
66	Multiple system atrophy laryngeal stridor treated with radiofrequency-assisted posterior cordotomy and arytenoidectomy. Clinical Autonomic Research, 0, , .	1.4	0